AI-Mind
Financiado
Intelligent digital tools for screening of brain connectivity and dementia risk...
Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people affected by mild cognitive impairment.
More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to n...
More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and dementia. The evolution of MCI differs from person to person; some remain stable or return to normal, but 50% progress to dementia within five years. Current practice lacks the necessary screening tools to identify those 50% at risk. The patient’s journey typically takes many years of inefficient clinical follow-ups before a conclusive diagnosis is finally reached.
AI-Mind will radically shorten this journey to 1 week through a digital solution that is able to provide a fast and accurate (>95%) prediction for the individual dementia risk. Our AI-Mind platform service, can be easily integrated into existing clinical practices and contains 2 new artificial-intelligence-based tools. The AI-Mind Connector identifies dysfunctional brain networks. The AI-Mind Predictor assesses demen-tia risk using data from the Connector, advanced cognitive tests, genetic biomarkers and important textual variables. Our aim is to set up a European clinical network that will upload patient data to the AI-Mind European cloud platform.
The consortium comprises excellent researchers in neuroscience and computer science, from 5 clinical cen-tres, who closely collaborate with 3 SMEs contributing unique technologies, an established data govern-ance body, and Alzheimer Europe. Together, they plan to deliver a medical device of class 2b that can reach TRL7 by the end of the project. AI-Mind represents a major step forward in the risk assessment of dementia. Clinicians will promptly advise therapies to delay the onset of disease, and patients will enjoy independent lives for longer. By offering a globally accessible, cheap and precise tool for dementia pre-diction, AI-Mind will improve the health care system and boost innovation by shifting the R&D of phar-maceutical organisations and other companies to preventive diagnostic methods and therapies for dementia.
ver más
28/02/2026
Líder desconocido
14M€
Duración del proyecto: 61 meses
Fecha Inicio: 2021-01-18
Fecha Fin: 2026-02-28
Fecha Fin: 2026-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2021-01-18
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
14M€
Líder del proyecto
Líder desconocido